Prelude Capital Management, LLC Uni Qure N.V. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $3,522 - $6,210	525 Added 4.37%	12,534 $84,000
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $133,540 - $266,599	12,009 New	12,009 $137,000
Q2 2021 Aug 16, 2021	SELL	$29.97 - $37.17 $179,820 - $223,020	-6,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $116,655 - $167,211	3,300 Added 122.22%	6,000 $217,000
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $121,662 - $182,898	2,700 New	2,700 $122,000
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $720 - $1,331	-18 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $668 - $1,343	18 New	18 $1,000
Q4 2017 Feb 14, 2018	SELL	$9.47 - $19.59 $9,394 - $19,433	-992 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$7.7 - $9.6 $7,638 - $9,523	992	992 $10,000

155

40.8M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $740M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.